A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Exclusion Criteria

• •1. Nodular lymphocyte predominant HL;
• •2. Patients received any form of anti-tumor therapy in the past;
• •3. Patients planning to receive radiotherapy or autologous stem cell transplantation;
• •4. With involvement of central nervous system (meninges or brain parenchyma);
• •5. Pregnant and lactating women and child-bearing patients who are unwilling to take contraceptive measures;
• •6. Patients with history of other tumors, except for cured cervical cancer orskin basal cell carcinoma; patients who have received organ transplantation;
• •7. Patients who have received symptomatic treatment of myelosuppressive toxicity within 7 days before enrollment;
• •8. Patients who have used any immunosuppressive drugs within 4 weeks before the first-dose treatment,
• •9. Patients with known active interstitial pneumonia;
• •10. Abnormal liver function (total bilirubin\>1.5×ULN, ALT/AST\>2.5×ULN or ALT/AST\>5×ULN for patients with liver invasion), abnormal renal function (serum creatinine\>1.5×ULN), abnormal electrolyte metabolism;
• •11. Peripheral neuropathy ≥ Grade 2;
• •12. Patients with a history of prolonged QT interval which is of clinical significance (male\> 450ms, female\> 470ms), ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI) within 1 year, congestive heart failure (CHF), patients with symptomatic coronary heart disease requiring drug therapy;
• •13. Patients with the end-diastolic width of fluid sonolucent area in pericardial cavity ≥10mm by cardiac B-ultrasonography;
• •14. Mentally disturbed/patients unable to give informed consent;
• •15. Patients who affect the evaluation of test results due to drug abuse or long-term alcohol abuse;
• •16. Participating in another interventional clinical study at the same time; Patients not suitable to participate in this trial by the judgment of investigators.